FDA clears Cosentyx for polymyalgia rheumatica, a first for the painful condition
Photo: Concierge Rheumatology (file photo)The U.S. Food and Drug Administration approved Cosentyx on Tuesday for adults with polymyalgia rheumatica who do not respond well to steroids or cannot taper off them, giving patients with the painful inflammatory condition a new option beyond long-term steroid use.
Cosentyx, known generically as secukinumab, is the first and only biologic that targets interleukin-17 — a protein involved in inflammation — to be approved for polymyalgia rheumatica, or PMR. The approval is the drug's 11th indication in the United States, Novartis announced.
PMR is a common inflammatory disease that mostly affects adults over 50. It causes pain and stiffness in the shoulders, neck and hips, and can make everyday movement difficult. Long-term steroids have been the standard treatment, but they can carry significant side effects and risks.
The approval covers the 150-milligram dose of Cosentyx for adults whose response to corticosteroids has been inadequate or who cannot tolerate a reduction in their steroid dose.
The decision rests on the Phase III REPLENISH trial, a global study conducted in 27 countries in which 381 patients were randomly assigned to receive Cosentyx or a placebo alongside a 24-week steroid taper. After a year, 40.5 percent of patients on the 150-milligram dose were in sustained remission, compared with 20.5 percent of those on placebo — roughly double the rate.
The trial results were published in the New England Journal of Medicine and presented at the 2026 European Alliance of Associations for Rheumatology Congress in June.
Serious side effects occurred in 15.9 percent of patients on the 150-milligram dose and in 14.2 percent of those on placebo, according to the trial data.
The PMR indication for Cosentyx is already approved in the European Union, and regulatory reviews are ongoing in Japan and other countries.
Sources: Novartis, "Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)" (Nov. 17, 2026, full text verified via GlobeNewswire); FirstWord Pharma, "Novartis' Cosentyx scores 11th FDA win, gaining approval for polymyalgia rheumatica" (Nov. 17, 2026, full text verified); MedPath, "FDA approves Novartis' Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica" (Nov. 17, 2026, full text verified).
Sponsored
